An investigation on behalf of investors of Homology Medicines, Inc. (NASDAQ: FIXX) shares over potential securities laws violations by Homology Medicines, Inc. and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Homology Medicines, Inc. (NASDAQ: FIXX) concerning whether a series of statements by Homology Medicines, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Bedford, MA based Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases.

On July 21, 2020, a report was published questioning statements by Homology Medicines, Inc. and its officers about the efficacy of HMI-102, the Companys lead product candidate for treatment of phenylketonuria. The report focused on Homologys HMI-102 dose escalation pheNIX trial, concluding that the Company concealed data showing HMI-102s lack of efficacy and indicating that the program was unlikely to proceed to commercialization. Among other evidence, the report cited an email from Homologys Chief Communications Officer appearing to indicate the Companys awareness that a HMI-102 high dose patient had adverted to the adverse efficacy issue in a social media post during April 2020.

Shares of Homology Medicines, Inc. (NASDAQ: FIXX) declined from $30.34 per share in March 2019 to as low as $9.19 per share on September 4, 2020.